TY - JOUR
T1 - Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff
T2 - multi-center open trial.
AU - Kanauchi, Osamu
AU - Mitsuyama, Keiichi
AU - Homma, Terasu
AU - Takahama, Kazuya
AU - Fujiyama, Yoshihide
AU - Andoh, Akira
AU - Araki, Yoshio
AU - Suga, Toshihiro
AU - Hibi, Toshifumi
AU - Naganuma, Makoto
AU - Asakura, Hitoshi
AU - Nakano, Hiroshi
AU - Shimoyama, Takashi
AU - Hida, Nobuyuki
AU - Haruma, Ken
AU - Koga, Hideki
AU - Sata, Michio
AU - Tomiyasu, Nobuo
AU - Toyonaga, Atsushi
AU - Fukuda, Masanobu
AU - Kojima, Atsushi
AU - Bamba, Tadao
PY - 2003/11
Y1 - 2003/11
N2 - Germinated barley foodstuff (GBF), which mainly consists of dietary fiber and glutamine-rich protein, is a prebiotic for ulcerative colitis (UC). In our previous study, we carried out a clinical trial of GBF with mildly to moderately active UC patients and showed that GBF treatment was able to attenuate the symptoms of UC in a relatively short-term. The aim of this study was to investigate the efficacy of long-term administration of GBF in the treatment of UC in a multi-center open trial. Twenty-one patients with mildly to moderately active UC received 20-30 g of GBF for 24 weeks in an open-label protocol while baseline treatments (5-amino-salicyrate compounds and/or steroids) were continued. The response to the GBF treatment was evaluated using a clinical scoring and after 24 weeks of observation, the GBF group showed a significant decrease in clinical activity index (especially, the degree of visible blood in stools and the presence of nocturnal diarrhea) compared with the control group (p<0.05). No side effects related to GBF were observed. In conclusion, GBF can reduce the clinical activity of UC over long-term as well as short-term administration. Nutraceutical GBF therapy may have a place in long-term management of UC, but controlled studies are needed to demonstrate its efficacy in the treatment of this disorder.
AB - Germinated barley foodstuff (GBF), which mainly consists of dietary fiber and glutamine-rich protein, is a prebiotic for ulcerative colitis (UC). In our previous study, we carried out a clinical trial of GBF with mildly to moderately active UC patients and showed that GBF treatment was able to attenuate the symptoms of UC in a relatively short-term. The aim of this study was to investigate the efficacy of long-term administration of GBF in the treatment of UC in a multi-center open trial. Twenty-one patients with mildly to moderately active UC received 20-30 g of GBF for 24 weeks in an open-label protocol while baseline treatments (5-amino-salicyrate compounds and/or steroids) were continued. The response to the GBF treatment was evaluated using a clinical scoring and after 24 weeks of observation, the GBF group showed a significant decrease in clinical activity index (especially, the degree of visible blood in stools and the presence of nocturnal diarrhea) compared with the control group (p<0.05). No side effects related to GBF were observed. In conclusion, GBF can reduce the clinical activity of UC over long-term as well as short-term administration. Nutraceutical GBF therapy may have a place in long-term management of UC, but controlled studies are needed to demonstrate its efficacy in the treatment of this disorder.
UR - http://www.scopus.com/inward/record.url?scp=2442470586&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2442470586&partnerID=8YFLogxK
U2 - 10.3892/ijmm.12.5.701
DO - 10.3892/ijmm.12.5.701
M3 - Article
C2 - 14532996
AN - SCOPUS:2442470586
SN - 1107-3756
VL - 12
SP - 701
EP - 704
JO - International Journal of Molecular Medicine
JF - International Journal of Molecular Medicine
IS - 5
ER -